TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: FMYPP    
Myocarditis/Pericarditis Panel

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

MYOCARDITIS-PERICARDITIS PANEL

 

COXSACKIE B(1-6) ANTIBODIES, SERUM

 

    REFERENCE RANGE: <1:8

 

    INTERPRETIVE CRITERIA:

            <1:8 Antibody Not Detected

            > or = 1:8 Antibody Detected

 

Single titers of > or = 1:32 are indicative of recent infection. Titers of 1:8 or 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.

 

This test was developed and its performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

 

ECHOVIRUS ANTIBODIES, SERUM

 

    REFERENCE RANGE: <1:8

 

    INTERPRETIVE CRITERIA:

            <1:8 Antibody Not Detected

            > or = 1:8 Antibody Detected

 

Single titers > or = 1:32 are indicative of recent infection. Titers of 1:8 and 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.

 

This test was developed and its performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

 

INFLUENZA TYPES A AND B ANTIBODIES, SERUM

 

    REFERENCE RANGE: <1:8

 

    INTERPRETIVE CRITERIA:

            <1:8 Antibody Not Detected

            > or = 1:8 Antibody Detected

 

Single titers of > or = 1:64 are indicative of recent infection. Titers of 1:8 to 1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis.

 

This test was developed and its performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

 

CHLAMYDOPHILA PNEUMONIAE ANTIBODIES (IgG, IgA, IgM)

 

    REFERENCE RANGE:    IgG <1:64

                                          IgA <1:16

                                          IgM <1:10

 

The immunofluorescent detection of specific antibodies to Chlamydophila pneumoniae may be complicated by cross-reactive antibodies, non-specific antibody stimulation, or past exposure to similar organisms such as C. psittaci and Chlamydia trachomatis. IgM titers of 1:10 or greater usually indicate recent infection, and any IgG titer may indicate past exposure. IgA is typically present at low titers during primary infection, but may be elevated in recurrent exposures or in chronic infection.